Huh, Seok Jae

D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity

Shi, Z., Weng, J., Niu, H., Yang, H., Liu, R., Weng, Y., Zhu, Q., Zhang, Y., Tao, L., Wang, Z., et al. (2023) · Cancer Science

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 38

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 22

Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.

Ruan, D.-Y., Lee, M. A., Deng, Y., Lee, K.-W., Millward, M., Grewal, J. S., Gadgeel, S. M., Sanborn, R. E., Hou, X., Wei, S., et al. (2023) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 12

Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation

Price, T., Grewal, J., Abed, A., Moore, M., Yeh, Y.-M., Gadgeel, S., Richardson, G., Underhill, C., Ganju, V., Lee, K.-W., et al. (2022) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 3